Results 141 to 150 of about 23,598 (268)

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova   +2 more
wiley   +1 more source

Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases

open access: yesCancer, Volume 132, Issue 10, 15 May 2026.
ABSTRACT Over the past decade, clonal hematopoiesis (CH) has gained substantial attention as a prevalent, age‐associated phenomenon with major implications for hematologic malignancy, cardiovascular disease, and mortality. CH arises from the clonal expansion of hematopoietic stem cells and progenitor cells harboring somatic mutations, most commonly in ...
Christian H. Nenninger   +7 more
wiley   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

open access: yesChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci   +5 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, Volume 20, Issue 5, Page 1220-1236, May 2026.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1457-1472, May 2026.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo   +10 more
wiley   +1 more source

MicroRNA‐Mediated Regulation of Brain Aging Hallmarks: Implications for Neurodegeneration and Neural Recovery

open access: yesBrain and Behavior, Volume 16, Issue 5, May 2026.
Hallmarks of brain aging regulated by microRNAs (miRNAs). This graphical abstract illustrates the central role of miRNAs in coordinating key biological processes associated with brain aging. miRNAs regulate multiple interconnected hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis and impaired ...
Mustafa T. Ardah   +7 more
wiley   +1 more source

MGL‐Based Drug Conjugate: A Novel Glycan‐Targeting Strategy for Potential Precision Cancer Therapy

open access: yesChemistryEurope, Volume 4, Issue 5, May 2026.
An engineered macrophage galactose‐type lectin (MGL)‐based conjugate (mMGL‐vcMMAE), incorporating an exposed cysteine for site‐specific drug linkage, preserves stability, binding profile, and affinity of the native MGL carbohydrate recognition domain. It also selectively targets Tn/STn‐expressing cancer cells and shows recognition of colorectal cancer ...
Carlos D. L. Lima   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy